middle.news
Immutep Secures $20M Upfront in Global Deal for Cancer Drug Efti
7:00am on Tuesday 9th of December, 2025 AEDT
•
Healthcare
Read Story
Immutep Secures $20M Upfront in Global Deal for Cancer Drug Efti
7:00am on Tuesday 9th of December, 2025 AEDT
Key Points
Exclusive licensing of Eftilagimod Alfa outside North America, Europe, Japan, Greater China
Upfront payment of USD 20 million to Immutep
Potential milestone payments up to USD 349.5 million plus double-digit royalties
Immutep retains manufacturing and rights in major pharmaceutical markets
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE